Skip to main content

Sanofi-Aventis S.A. ADR(SNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low44.00
Day High44.63
Open:44.08
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Sanofi-Aventis S.A. ADR

Select a category then submit the form to load news
Tipranks
Sanofi Details CEO Paul Hudson’s February 2026 Departure Terms and Equity Awards
Zacks Investment Research
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Zacks Investment Research
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Motley Fool
The Best Healthcare Stock to Invest $1,000 in Right Now
Zacks Investment Research
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
Zacks Investment Research
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
Tipranks
Sanofi’s New Pediatric Fitusiran Trial Signals a Long-Term Hemophilia Push
Tipranks
Sanofi Real-World Data Show Durable Two-Season Protection From Beyfortus in Infants
Motley Fool
1 No-Brainer Biotech Stock To Buy Today and Never Sell
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ocular Therapeutix (OCUL) and Sanofi (SNY)
Zacks Investment Research
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
Tipranks
Sanofi’s Real-World COPD Study on Dupilumab: What Investors Should Watch
Tipranks
Sanofi Wins U.S. Breakthrough and Japan Orphan Status for Rilzabrutinib in Rare Anemia
Stock Target Advisor
Stocks Rebound as Traders Remain Cautious on AI-Disruption-Market Analysis for February 17th, 2026
Stocks Rebound as Traders Remain Cautious on AI-Disruption-Market Analysis for February 17th, 2026
Tipranks
Sanofi Names Belén Garijo as New CEO, Effective After April Shareholder Meeting
Tipranks
Sanofi (SNYNF) Receives a Hold from Barclays
Zacks Investment Research
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Tipranks
Regeneron and Sanofi Advance Kevzara Into Polymyalgia Rheumatica, Eyeing New Growth Channel
Tipranks
Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
Tipranks
Sanofi Wins Positive EU CHMP Opinion for Rezurock in Chronic Graft-Versus-Host Disease
Tipranks
Kepler Capital Sticks to Its Hold Rating for Sanofi (SNYNF)
Tipranks
Kepler Capital Keeps Their Hold Rating on Sanofi (SNYNF)
Tipranks
Sanofi Earnings Call: Profitable Growth Amid Rising Risks
Zacks Investment Research
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
Tipranks
Sanofi Posts Strong 2025 Sales and EPS Growth, Sets High-Single-Digit Outlook for 2026
Tipranks
Sanofi (SNYNF) Gets a Hold from J.P. Morgan
Tipranks
Jefferies Sticks to Their Buy Rating for Sanofi (SNYNF)
Motley Fool
This Infrastructure Stock Surged Nearly 40% in One Year -- and One Fund Sold $11 Million in Shares
Tipranks
Sanofi Advances PCV21 Vaccine Trial in Sickle Cell Children, Targeting an Edge in Pneumococcal Protection
Tipranks
Deutsche Bank Remains a Buy on Sanofi (SNYNF)
Tipranks
Sanofi Advances Amlitelimab Toward Global Filings After Positive Phase 3 Atopic Dermatitis Data
Tipranks
Sanofi (SNYNF) Receives a Buy from Berenberg Bank

Profile

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.